Elizabeth G. Nabel
Known title: DirectorCIK: 0001619929
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
MiniMed completes separation from Medtronic. Medtronic has finalized the separation of its MiniMed insulin pump business, which is now operating as an independent company with a new board of directors. This corporate restructuring marks a significant shift in Medtronic's portfolio structure. Meanwhile, the company was named to the TIME Best Inventions of 2026 list for its Stealth AXiS surgical system and Corsano wearable, highlighting continued innovation in its remaining product lines.
Transaction History
| MRNA | ▲ Buy | Option Exercise | 16,233 | — | 4/30/2026 | View on chart |
| MDT | ▼ Sell | Tax Withholding | 207 | $17K | 4/28/2026 | View on chart |
| MDT | ▲ Buy | Grant | 2,111 | $0 | 4/27/2026 | View on chart |
| MRNA | ▲ Buy | Option Exercise | 979 | — | 4/30/2025 | View on chart |
| MDT | ▼ Sell | Tax Withholding | 216 | $18K | 4/29/2025 | View on chart |
| MDT | ▲ Buy | Grant | 2,083 | $175K | 4/28/2025 | View on chart |
| MRNA | ▲ Buy | Option Exercise | 732 | — | 5/3/2024 | View on chart |
| MDT | ▼ Sell | Tax Withholding | 192 | $16K | 5/1/2024 | View on chart |
| MDT | ▲ Buy | Grant | 2,165 | $175K | 4/29/2024 | View on chart |
| MDT | ▼ Sell | Tax Withholding | 169 | $15K | 5/2/2023 | View on chart |
| MDT | ▲ Buy | Grant | 1,930 | $175K | 5/1/2023 | View on chart |
| MRNA | ▲ Buy | Option Exercise | 670 | — | 4/28/2023 | View on chart |
| MDT | ▼ Sell | Tax Withholding | 262 | $27K | 5/3/2022 | View on chart |
| MDT | ▲ Buy | Grant | 1,697 | $0 | 5/2/2022 | View on chart |
| MRNA | ▲ Buy | Option Exercise | 703 | $0 | 4/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Moderna faces stock dip amid cancer vaccine news and cash position
Recent articles note that Moderna holds a large cash reserve while advancing a deep cancer pipeline. A Phase 3 trial of its cancer vaccine reported positive results, which could broaden the company's product base. At the same time, the stock has fallen sharply, reflecting broader weakness in biotech and a pause in the recent rally. The decline occurs despite the cash strength and analyst price targets that remain well above current levels.
Moderna faces stock dip amid cancer vaccine news and cash position. Recent articles note that Moderna holds a large cash reserve while advancing a deep cancer pipeline. A Phase 3 trial of its cancer vaccine reported positive results, which could broaden the company's product base. At the same time, the stock has fallen sharply, reflecting broader weakness in biotech and a pause in the recent rally. The decline occurs despite the cash strength and analyst price targets that remain well above current levels.